Dry Powder Inhaler Devices Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies

Dry Powder Inhaler Devices Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies


Summary

Dry powder inhaler devices deliver medication to the lungs in the form of a dry powder. GlobalData's Medical Devices sector report, “Dry Powder Inhaler Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update provides comprehensive information about the Dry Powder Inhaler Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

The Dry Powder Inhaler Devices report provides key information and data related to:

Extensive coverage of the Dry Powder Inhaler Devices under development

Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths, and estimated approval dates

Reviews of major players involved in the pipeline product development.

Provides key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and the number of trials of the major Dry Powder Inhaler Devices pipeline products.

Review of Recent Developments in the segment / industry

The Dry Powder Inhaler Devices report enables you to:

Access significant competitor information, analysis, and insights to improve your R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage

Identify and understand important and diverse types of Dry Powder Inhaler Devices under development

Formulate market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

The GlobalData Differentiation

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

The data and analysis within this report are driven by GlobalData Medical Intelligence Center (GDMIC) database. GDMIC gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following:
  • 15,000+ data tables showing market size across more than 780 medical equipment segments and 39 countries, from 2015 and forecast to 2025
  • 6,700+ industry-leading analysis reports covering sector reports, medipoint reports, country analysis, expert insights and industry analysis (devices and procedures) reports
  • 64,000+ medical equipment company profiles
  • 5,600+ company profiles of medical equipment manufacturers in China and India
  • 2,200+ company profiles of medical equipment manufacturers in Japan
  • 1,200+ companies’ revenue splits and market shares
  • 1,600+ quarterly and annual medical equipment company financials
  • 850+ medical equipment company SWOTs
  • 28,000+ pipeline product profiles
  • 56,400+ marketed product profiles
  • 47,000+ clinical trials
  • 41,500+ trial investigators
  • 7,000+ reports on companies with products in development
  • 44,000+ deals in the medical equipment industry
  • 1,100+ surgical and diagnostic procedures by therapy area
  • 50+ key healthcare indicators by country
  • 431,000+ Themes Content Items
  • 600+ Influencers
  • 1,900+ Analysts & Researchers
  • 0.5m+ Community Members
  • 141,000+ Macroeconomic Indicators
  • 1,013,000+ City Indicators
Scope
  • Extensive coverage of the Dry Powder Inhaler Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Dry Powder Inhaler Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Dry Powder Inhaler Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date


  • About GlobalData
  • Introduction
    • Dry Powder Inhaler Devices Overview
  • Products under Development
    • Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
      • Table Figure 1: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
      • Table Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
    • Dry Powder Inhaler Devices - Pipeline Products by Territory
      • Table Figure 2: Dry Powder Inhaler Devices - Pipeline Products by Territory
      • Table Dry Powder Inhaler Devices - Pipeline Products by Territory
    • Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
      • Table Figure 3: Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
      • Table Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
    • Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
      • Table Figure 4: Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
      • Table Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
    • Dry Powder Inhaler Devices - Ongoing Clinical Trials
      • Table Figure 5: Dry Powder Inhaler Devices - Ongoing Clinical Trials
      • Table Dry Powder Inhaler Devices - Ongoing Clinical Trials
  • Dry Powder Inhaler Devices - Pipeline Products under Development by Companies
    • Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development
      • Table Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development
    • Dry Powder Inhaler Devices - Companies Pipeline Products by Stage of Development
      • Table Dry Powder Inhaler Devices - Companies Pipeline Products by Stage of Development
  • Dry Powder Inhaler Devices Companies and Product Overview
    • Acorda Therapeutics Inc Company Overview
      • Acorda Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Acorda Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table INBRIJA - Product Status
        • Table INBRIJA - Product Description
        • Table Acorda Therapeutics Inc - Ongoing Clinical Trials Overview
        • Table INBRIJA - Usability of Levodopa Cyclops Compared to INBRIJA During an Off Episode in Parkinson's Disease Patients
    • Advent Pharmaceuticals Pty Ltd Company Overview
      • Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table g60 Dry Powder Inhaler - Product Status
        • Table g60 Dry Powder Inhaler - Product Description
    • Aespira Ltd. Company Overview
      • Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview
        • Table resQhaler - Product Status
        • Table resQhaler - Product Description
    • AKELA Pharma Inc. (Inactive) Company Overview
      • AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
        • Table AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
        • Table Fentanyl TAIFUN Inhaler - Product Status
        • Table Fentanyl TAIFUN Inhaler - Product Description
    • Bayer AG Company Overview
      • Bayer AG Pipeline Products & Ongoing Clinical Trials Overview
        • Table Bayer AG Pipeline Products & Ongoing Clinical Trials Overview
        • Table Ciprofloxacin Dry Powder Inhaler - Product Status
        • Table Ciprofloxacin Dry Powder Inhaler - Product Description
    • Cambridge Healthcare Innovations Ltd Company Overview
      • Cambridge Healthcare Innovations Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Cambridge Healthcare Innovations Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table aeolus Dry-Powder Inhaler (DPI) - Product Status
        • Table aeolus Dry-Powder Inhaler (DPI) - Product Description
    • Creare LLC Company Overview
      • Creare LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Creare LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Intranasal Dry Powder Inhaler - Product Status
        • Table Intranasal Dry Powder Inhaler - Product Description
    • DMK Pharmaceuticals Corp Company Overview
      • DMK Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table DMK Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table APC-4000 Fluticasone Dry Powder Inhaler - Product Status
        • Table APC-4000 Fluticasone Dry Powder Inhaler - Product Description
    • Eli Lilly and Co Company Overview
      • Eli Lilly and Co Pipeline Products & Ongoing Clinical Trials Overview
        • Table Eli Lilly and Co Pipeline Products & Ongoing Clinical Trials Overview
        • Table Nasal Glucagon Delivery System - Product Status
        • Table Nasal Glucagon Delivery System - Product Description
    • Glenmark Pharmaceuticals Ltd Company Overview
      • Glenmark Pharmaceuticals Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Glenmark Pharmaceuticals Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Tiogiva - Product Status
        • Table Tiogiva - Product Description
    • GSK plc Company Overview
      • GSK plc Pipeline Products & Ongoing Clinical Trials Overview
        • Table GSK plc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Gemini Multi-Dose Combination Inhaler - Product Status
        • Table Gemini Multi-Dose Combination Inhaler - Product Description
    • Hovione Technology Ltd Company Overview
      • Hovione Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Hovione Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Papillon DPI - Product Status
        • Table Papillon DPI - Product Description
    • Iconovo AB Company Overview
      • Iconovo AB Pipeline Products & Ongoing Clinical Trials Overview
        • Table Iconovo AB Pipeline Products & Ongoing Clinical Trials Overview
        • Table ICOcap - Product Status
        • Table ICOcap - Product Description
        • Table ICOone - Product Status
        • Table ICOone - Product Description
        • Table ICOone - Oxytocin - Product Status
        • Table ICOone - Oxytocin - Product Description
        • Table ICOpre - Product Status
        • Table ICOpre - Product Description
        • Table ICOres - Product Status
        • Table ICOres - Product Description
        • Table Multi-Dose Delivery Device - Product Status
        • Table Multi-Dose Delivery Device - Product Description
        • Table Iconovo AB - Ongoing Clinical Trials Overview
        • Table ICOone - A Feasibility Study with Affilogic for the Development of Inhalable Nanofitin-based Biotherapies
        • Table ICOone - Oxytocin - A Randomized, Single-Center, Partially Single-Blind Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Single and Repeated Doses of Oxytocin Administered via Inhalation or Intravenous or Intramuscular Administration in Healthy Female
    • Lupin Pharmaceuticals Inc Company Overview
      • Lupin Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Lupin Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Dry Powder Inhaler 1 - Product Status
        • Table Dry Powder Inhaler 1 - Product Description
        • Table Dry Powder Inhaler 2 - Product Status
        • Table Dry Powder Inhaler 2 - Product Description
        • Table Tiotropium DPI - Product Status
        • Table Tiotropium DPI - Product Description
    • MannKind Corp Company Overview
      • MannKind Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table MannKind Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Afrezza - Pediatric Use - Product Status
        • Table Afrezza - Pediatric Use - Product Description
        • Table Afrezza Inhaler - Product Status
        • Table Afrezza Inhaler - Product Description
        • Table Treprostinil Technosphere - Product Status
        • Table Treprostinil Technosphere - Product Description
        • Table MannKind Corp - Ongoing Clinical Trials Overview
        • Table Afrezza Inhaler - INHALE-3: A 17-Week Randomized Trial and a 13-Week Extension, Evaluating the Efficacy and Safety of Inhaled Insulin (Afrezza) Combined with Insulin Degludec Versus Usual Care in Adults with Type 1 Diabetes
    • Monash University Company Overview
      • Monash University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Monash University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Aerosol Delivery System - Product Status
        • Table Aerosol Delivery System - Product Description
    • Nektar Therapeutics Company Overview
      • Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview
        • Table Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview
        • Table NKTR-061 - Product Status
        • Table NKTR-061 - Product Description
    • Ology Bioservices Inc Company Overview
      • Ology Bioservices Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Ology Bioservices Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table GelVac Intranasal Powder Vaccine Delivery System - Product Status
        • Table GelVac Intranasal Powder Vaccine Delivery System - Product Description
        • Table NanoGENT - Product Status
        • Table NanoGENT - Product Description
    • OPKO Health Inc Company Overview
      • OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Inspiromatic - Product Status
        • Table Inspiromatic - Product Description
    • OtiTopic Inc Company Overview
      • OtiTopic Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table OtiTopic Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table ASPRIHALE - Product Status
        • Table ASPRIHALE - Product Description
        • Table OtiTopic Inc - Ongoing Clinical Trials Overview
        • Table ASPRIHALE - A Phase I, Single-dose, Open-label, Pilot Study to Compare the Pharmacodynamics and Pharmacokinetics of Acetylsalicylic Acid Inhalation Powder with Non-enteric-coated Chewable Aspirin in Healthy Adults
    • Phargentis SA Company Overview
      • Phargentis SA Pipeline Products & Ongoing Clinical Trials Overview
        • Table Phargentis SA Pipeline Products & Ongoing Clinical Trials Overview
        • Table Glide DPI - Product Status
        • Table Glide DPI - Product Description
        • Table Indacaterol/Glycopyrronium DPI - Product Status
        • Table Indacaterol/Glycopyrronium DPI - Product Description
    • Pharmaxis Ltd Company Overview
      • Pharmaxis Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Pharmaxis Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Orbital Dry Powder Inhaler - Product Status
        • Table Orbital Dry Powder Inhaler - Product Description
    • PureIMS BV Company Overview
      • PureIMS BV Pipeline Products & Ongoing Clinical Trials Overview
        • Table PureIMS BV Pipeline Products & Ongoing Clinical Trials Overview
        • Table Amikacin Cyclops - Product Status
        • Table Amikacin Cyclops - Product Description
        • Table Epinephrine Cyclops - Product Status
        • Table Epinephrine Cyclops - Product Description
        • Table Levodopa Cyclops - Product Status
        • Table Levodopa Cyclops - Product Description
        • Table Tobramycin Cyclops - Product Status
        • Table Tobramycin Cyclops - Product Description
        • Table PureIMS BV - Ongoing Clinical Trials Overview
        • Table Levodopa Cyclops - Usability of Levodopa Cyclops Compared to INBRIJA During an Off Episode in Parkinson's Disease Patients
    • Quench Medical Inc Company Overview
      • Quench Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Quench Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Dry Powder Inhaler - Product Status(Quench Medical Inc)
        • Table Dry Powder Inhaler - Product Description(Quench Medical Inc)
    • Respira Therapeutics Inc Company Overview
      • Respira Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Respira Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table RT234 AOS DPI - Product Status
        • Table RT234 AOS DPI - Product Description
    • Respirent Pharmaceuticals Co Ltd Company Overview
      • Respirent Pharmaceuticals Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Respirent Pharmaceuticals Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Flovent Diskus - Generic Version - Product Status
        • Table Flovent Diskus - Generic Version - Product Description
        • Table Respirent Pharmaceuticals Co Ltd - Ongoing Clinical Trials Overview
        • Table Flovent Diskus - Generic Version - A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Twoperiod, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent
    • Sandoz International GmbH Company Overview
      • Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table Solis Multi-Dose Dry Powder Inhaler - Product Status
        • Table Solis Multi-Dose Dry Powder Inhaler - Product Description
        • Table Unit-Dose Dry Powder Inhaler - Product Status
        • Table Unit-Dose Dry Powder Inhaler - Product Description
    • Sheffield Hallam University Company Overview
      • Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Dry Powder Inhaler - Product Status(Sheffield Hallam University)
        • Table Dry Powder Inhaler - Product Description(Sheffield Hallam University)
    • Shin Nippon Biomedical Laboratories Ltd Company Overview
      • Shin Nippon Biomedical Laboratories Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Shin Nippon Biomedical Laboratories Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table STS101 Dry Powder Delivery Device - Product Status
        • Table STS101 Dry Powder Delivery Device - Product Description
    • Spyryx Biosciences Inc (Inactive) Company Overview
      • Spyryx Biosciences Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
        • Table Spyryx Biosciences Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
        • Table SPX-250 Dry Powder Inhaler - Product Status
        • Table SPX-250 Dry Powder Inhaler - Product Description
    • Teva Pharmaceutical Industries Ltd Company Overview
      • Teva Pharmaceutical Industries Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Teva Pharmaceutical Industries Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table AirDuo Digihaler - Product Status
        • Table AirDuo Digihaler - Product Description
        • Table ArmonAir Digihaler - Product Status
        • Table ArmonAir Digihaler - Product Description
        • Table ProAir Digihaler - Product Status
        • Table ProAir Digihaler - Product Description
        • Table Teva Pharmaceutical Industries Ltd - Ongoing Clinical Trials Overview
        • Table ProAir Digihaler - Utilizing Advances in Digital Inhaler Technology to Understand Heterogeneous Treatment Responses to Biologics in Severe Asthma
        • Table AirDuo Digihaler - Utilizing Advances in Digital Inhaler Technology to Understand Heterogeneous Treatment Responses to Biologics in Severe Asthma
    • Transpire Bio Inc Company Overview
      • Transpire Bio Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Transpire Bio Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Dry Powder Inhaler (DPI) - Asthma COPD - Product Status
        • Table Dry Powder Inhaler (DPI) - Asthma COPD - Product Description
        • Table Dry Powder Inhaler (DPI) - COPD - Product Status
        • Table Dry Powder Inhaler (DPI) - COPD - Product Description
    • University of Kansas Company Overview
      • University of Kansas Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Kansas Pipeline Products & Ongoing Clinical Trials Overview
        • Table Dry Powder Inhaler - Product Status(University of Kansas)
        • Table Dry Powder Inhaler - Product Description(University of Kansas)
    • University of Sydney Company Overview
      • University of Sydney Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Sydney Pipeline Products & Ongoing Clinical Trials Overview
        • Table Dry Powder Inhaler - Product Status(University of Sydney)
        • Table Dry Powder Inhaler - Product Description(University of Sydney)
    • University of Texas Medical Branch at Galveston Company Overview
      • University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview
        • Table Dry Powder Drug Delivery System - Product Status
        • Table Dry Powder Drug Delivery System - Product Description
    • Vectura Group Plc Company Overview
      • Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Digitally - Connected LOMI Device - Product Status
        • Table Digitally - Connected LOMI Device - Product Description
        • Table MRX006 - Multidose Combined DPI Inhaler - Product Status
        • Table MRX006 - Multidose Combined DPI Inhaler - Product Description
        • Table SKP-2075 - Product Status
        • Table SKP-2075 - Product Description
    • Verona Pharma Plc Company Overview
      • Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview
        • Table RPL554 - Dry Powder Inhaler - Product Status
        • Table RPL554 - Dry Powder Inhaler - Product Description
    • Virginia Commonwealth University Company Overview
      • Table Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview
      • Table Drug Delivery Device - Cystic Fibrosis - Product Status
      • Table Drug Delivery Device - Cystic Fibrosis - Product Description
      • Table Dry Powder Inhaler - Product Status(Virginia Commonwealth University)
      • Table Dry Powder Inhaler - Product Description(Virginia Commonwealth University)
  • Dry Powder Inhaler Devices- Recent Developments
    • Oct 30, 2023: Chiesi Announces New Senior Level Changes to Leadership Team
    • Oct 24, 2023: 3M Reports Third Quarter 2023 Results; Company Increases Full Year Adjusted Earnings and Cash Flow Expectations
    • Oct 19, 2023: DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth
    • Oct 16, 2023: Orion publishes Interim Report for January-September 2023 on Thursday 26 October 2023
    • Sep 28, 2023: Teva Announces Changes to Executive Management Team
    • Sep 05, 2023: MannKind Announces Participation at Upcoming Conferences
    • Aug 28, 2023: Novartis to Let Go 100 Employees in Latest Round of Layoffs
    • Aug 23, 2023: 3M Appoints Carrie Cox as Chairman of the Board of Directors of the Independent Health Care Company
    • Aug 22, 2023: Bryan Hanson Named CEO of 3M's Health Care Business Group
    • Aug 17, 2023: Ziccum to present at Investor Conference BioFuture 2023 in New York
    • Aug 01, 2023: MannKind Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
    • Jul 31, 2023: MannKind to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
    • Jul 07, 2023: Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair
    • Jul 05, 2023: Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2
    • Jul 04, 2023: Orion Publishes Half-year Financial Report for January - June 2023
    • Jun 02, 2023: Ziccum appoints senior biopharma executive as new CFO
    • May 24, 2023: Ziccum: Bulletin from the Annual General Meeting
    • May 24, 2023: Dr. Burkhard Blank joins MannKind as executive vice president of research & development and chief medical officer
    • May 15, 2023: Adamis Pharmaceuticals reports Q1 2023 financial results and provides corporate update
    • May 09, 2023: 3M annual meeting highlights business portfolio, innovation, and actions to drive future performance
    • May 09, 2023: Mannkind reports 2023 first quarter financial results
    • May 08, 2023: Adamis Pharmaceuticals schedules Q1 2023 financial results conference call and corporate update
    • May 03, 2023: Hovione and H&T Presspart extend partnership to advance high efficiency device technology for Dry Powder Inhalation formulation delivery
    • May 02, 2023: MannKind Corp. to hold 2023 first quarter financial results conference call on May 9, 2023
    • Apr 28, 2023: Iconovo Publishes Annual Report for 2022
    • Apr 28, 2023: Iconovo Announces Interim Report January - March 2023
    • Apr 26, 2023: Ziccum announces releases of interim report Q1 2023
    • Apr 25, 2023: OPKO Health to report Q1 2023 financial results on May 3, 2023
    • Apr 25, 2023: 3M announces more layoffs
    • Apr 20, 2023: Iconovo announces notice to the annual general meeting
    • Apr 13, 2023: Orion publishes Interim Report for January-March 2023 on Thursday 27 April 2023
    • Apr 04, 2023: PureIMS secures funding to develop inhalation product
    • Mar 27, 2023: Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer
    • Mar 14, 2023: Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
    • Mar 10, 2023: GSK publishes Annual Report 2022
    • Feb 28, 2023: Orion Group Announces Financial Statement documents 2022, Corporate Governance Statement and Remuneration Report published
    • Feb 23, 2023: MannKind Corp. Reports 2022 Fourth Quarter and Full Year Financial Results
    • Feb 17, 2023: ZICCUM releases Annual Report 2022
    • Feb 16, 2023: OPKO Health to Report Fourth Quarter 2022 Financial Results on February 23, 2023
    • Feb 16, 2023: MannKind Corp. to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
    • Feb 09, 2023: Orion Group Announces Financial Statement Release 2022
    • Feb 08, 2023: Iconovo Announces Financial Statement 1 January to 31 December 2022
    • Feb 01, 2023: Novartis Announces Annual Report 2022
    • Jan 30, 2023: Chiesi appoints Giuseppe Accogli as new Group CEO
    • Jan 26, 2023: Orion publishes Financial Statement Release for 2022 on Thursday 9 February 2023
    • Jan 24, 2023: 3M Reports Fourth-Quarter and Full-Year 2022 Results
    • Jan 24, 2023: 3M Lays off 2500 employees
    • Jan 12, 2023: Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023 Financial Guidance at 8 a.m. ET on February 8, 2023
    • Dec 15, 2022: Iconovo appoints Henrik Damkjær Simonsen as Chief Financial Officer
    • Nov 21, 2022: Teva Announces Appointment of Richard Francis as President and CEO
    • Nov 21, 2022: Teva Pharma Appoints Novartis, Biogen Vet as New President and CEO
    • Nov 16, 2022: Iconovo appoints Peter Akerlund as acting CFO
    • Nov 14, 2022: Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
  • Appendix
    • Methodology
      • Table Glossary
    • About GlobalData
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings